EP Patent

EP3955888A1 — Method for treating neonatal opiod withdrawal syndrome

Assigned to Chiesi Farmaceutici SpA · Expires 2022-02-23 · 4y expired

What this patent protects

Formulations comprising buprenorphine are useful for treating opioid withdrawal syndrome.

USPTO Abstract

Formulations comprising buprenorphine are useful for treating opioid withdrawal syndrome.

Drugs covered by this patent

Patent Metadata

Patent number: EP3955888A1
Jurisdiction: EP
Classification: —
Expires: 2022-02-23
Drug substance claim: No
Drug product claim: No
Assignee: Chiesi Farmaceutici SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.